Compounds · subcategory

Oral incretins

Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data.

24 topics1,035 posts9 solved Moderators: s.leclerc, j.mwangi About this category

oral semaglutide orforglipron PIONEER programme SOUL trial randomised trial

24 topics

Topic	Participants	Replies	Views	Activity
About the Oral incretins category oral semaglutide orforglipron PIONEER programme Pinned Wiki Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…		4	6.2k	20d
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…		2	17k	6h
The SOUL trial and oral semaglutide cardiovascular outcomes orforglipron oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it…		2	7.1k	9h
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one PIONEER programme SOUL trial randomised trial orforglipron Solved PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…	+25	29	22k	1d
Why fasting instructions for oral semaglutide are not optional advice PIONEER programme orforglipron randomised trial SOUL trial Solved Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016)…	+70	74	1.1k	23d
Why oral semaglutide needs an absorption enhancer at all — one year on randomised trial SOUL trial oral semaglutide PIONEER programme Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…	+11	15	17k	24d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…	+27	31	17k	25d
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on PIONEER programme SOUL trial orforglipron Solved Asking directly, because I could not find a straight answer: Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited…	+16	20	18k	2mo
Oral semaglutide bioavailability and its variability between people SOUL trial oral semaglutide randomised trial Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in…	+44	48	574	3mo
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes randomised trial SOUL trial oral semaglutide orforglipron Solved The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…	+100	104	4.2k	5mo
Dose numbers for oral formulations are not comparable to injectable ones orforglipron PIONEER programme SOUL trial On the subject in the title: Dose numbers for oral formulations are not comparable to injectable ones Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+19	23	39k	6mo
Why oral semaglutide needs an absorption enhancer at all randomised trial orforglipron oral semaglutide SOUL trial Solved Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of…	+59	65	61k	7mo
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one oral semaglutide randomised trial PIONEER programme SOUL trial Solved Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021)…	+130	135	11k	7mo
Oral versus injectable exposure: comparing apples to a different fruit oral semaglutide SOUL trial PIONEER programme randomised trial Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…	+19	23	332	8mo
Why fasting instructions for oral semaglutide are not optional advice — does this still hold? orforglipron SOUL trial PIONEER programme randomised trial Solved Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Session topic: PIONEER 6 ( N Engl J Med , 2019).…	+98	106	3.1k	10mo
Food effects on oral incretin absorption: what is documented PIONEER programme SOUL trial randomised trial oral semaglutide Solved Under review On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…		2	4.4k	12mo
Revisiting: Food effects on oral incretin absorption: what is documented oral semaglutide PIONEER programme SOUL trial orforglipron Under review Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…	+6	10	51k	13mo
Why oral semaglutide needs an absorption enhancer at all — what changed since randomised trial PIONEER programme SOUL trial Solved Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it before…		2	61k	14mo
SNAC and the mechanism of oral peptide absorption — the long version oral semaglutide randomised trial orforglipron SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+32	36	6.8k	16mo
SNAC and the mechanism of oral peptide absorption orforglipron randomised trial PIONEER programme oral semaglutide On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…	+13	17	14k	17mo
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset randomised trial orforglipron PIONEER programme Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl…	+48	52	59k	18mo
Oral semaglutide bioavailability and its variability between people — a second dataset randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? orforglipron SOUL trial oral semaglutide PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session…	+23	27	4.8k	22mo
Orforglipron as a non-peptide: what changes when the molecule is small orforglipron SOUL trial PIONEER programme On the subject in the title: Orforglipron as a non-peptide: what changes when the molecule is small Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURMOUNT-4 ( JAMA ,…	+26	30	26k	23mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →